Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics

O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors

FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment

Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor

Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients

LYMPHIR addresses a clear clinical need in a disease with limited treatment options

Belite Bio reports landmark phase 3 success for Stargardt Disease therapy

Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging

Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval

Now a test that offers new precision in prostate cancer detection

Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers

Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM

Roche expands Veeva partnership with global rollout of AI-driven Vault CRM

Roche says the move marks a step forward in its digital transformation strategy

Cipla opens India's First dedicated lung health diagnostics center in Delhi

Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety

Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight

Renalys Pharma reports major phase III success for Sparsentan in Japanese IgA nephropathy patients

The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio